

Form 144

FORM 144

NOTICE OF PROPOSED SALE OF SECURITIES
PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

144: Filer Information

Filer CIK 0001741987
Filer CCC XXXXXXXXX
Is this a LIVE or TEST Filing? LIVE TEST

Submission Contact Information

Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer Arcutis Biotherapeutics, Inc.
SEC File Number 001-39186
Address of Issuer 3027 TOWNSGATE ROAD
SUITE 300
WESTLAKE VILLAGE
CALIFORNIA
91361
Phone 805-418-5006
Name of Person for Whose Account the Securities are To Be Sold Burnett Patrick

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Merrill Lynch 8890 Lyra Dr. 5th Floor Columbus OH 43240	100	1003.00	117044591	11/15/2024	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition	Name of Person from Whom	Is this	Date Donor	Amount of Securities	Date of Payment	Nature of Payment *
--------------------	-------------------	-----------------------	--------------------------	---------	------------	----------------------	-----------------	---------------------

Transaction	Acquired	a	Acquired	Acquired
		Gift?		
Common	01/12/2024	Stock Option Exercise	Arcutis Biotherapeutics, Inc	100 01/12/2024 Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Merrill Lynch 8890 Lyra Dr 5th Floor Columbus OH 43240	Common	11/04/2024	15441	133626.00
Merrill Lynch 8890 Lyra Drive 5th Floor Columbus OH 43240	Common	08/19/2024	1728	14266.00
Merrill Lynch 8890 Lyra Drive 5th Floor Columbus OH 43240	Common	11/14/2024	50749	522433.00
Merrill Lynch 8890 Lyra Drive 5th Floor Columbus OH 43240	Common	11/14/2024	18377	189181.00

144: Remarks and Signature

Remarks

Date of Notice 11/15/2024

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

Patrick Burnett

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)